Skip to main content
. 2020 Jul 30;5(31):19778–19784. doi: 10.1021/acsomega.0c02555

Figure 5.

Figure 5

Antitumor activity of a palmitic acid-conjugated repebody in H1650 tumor xenograft mice. (A) Experimental schedule for the assessment of tumor growth level when injected with Pal-Rb. (B,C) Effect of Pal-Rb on the tumor growth in xenograft mice. Pal-Rb was injected intravenously (10 mg/kg, n = 5 for each group), and tumor growth was monitored in every 3 days for 27 days. WT-Rb and PBS were used as controls. Pal-Rb resulted in a significant suppression of tumor growth compared to WT-Rb (**p < 0.01). Error bars describe mean ± standard deviation. (D) Body weight changes of mice injected with Pal-Rb. The body weight change was monitored for 27 days. (E) Hepatotoxicity of Pal-Rb. Blood was analyzed for aspartate aminotransferase (ALT) and alanine aminotransferase (AST) levels at day 27. (F,G) Nephrotoxicity of Pal-Rb. Blood was analyzed for creatine and BUN levels at day 27. Error bars describe mean ± standard deviation.